

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alexandra, Vignua 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10′017,822	12/12/2001	Raymond P. Zinkowski	98,614-D	6751	
75	590 08/20/2003				
Steven J. Sarussi			EXAMINER		
32nd Floor	ehnen Hulbert & Berghoff	•	KIM, YO	KIM, YOUNG J	
300 S. Wacker Drive Chicago, IL 60606			ART UNIT	PAPER NUMBER	
Cincago, IL o	3000		1637	2	
			DATE MAILED: 08/20/2003	<b>i</b>	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
_	10/017,822	ZINKOWSKI ET AL.	
Office Action Summary	Examiner	Art Unit	
	Young J. Kim	1637	
The MAILING DATE of this communicatio	_		
Period for Reply			
A SHORTENED STATUTORY PERIOD FOR R THE MAILING DATE OF THIS COMMUNICATI  - Extensions of time may be available under the provisions of 37 C after SIX (6) MONTHS from the mailing date of this communication  - If the period for reply specified above is less than thirty (30) days  - If NO period for reply is specified above, the maximum statutory in the second of the	ON. ERR 1.136(a) In no event, however, may a on. , a reply within the statutory minimum of thir period will apply and will expire SIX (6) MON statute, cause the application to become Al	reply be timely filed ty (30) days will be considered timely. NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133)	
1) Responsive to communication(s) filed or	n		
2a) This action is <b>FINAL</b> . 2b) ∑	This action is non-final.		
3) Since this application is in condition for a			
closed in accordance with the practice u <b>Disposition of Claims</b>	nder Ex parte Quayre, 1955 C.	D. 11, 433 O.G. 213.	
4) Claim(s) 1-37 is/are pending in the application	cation.		
4a) Of the above claim(s) is/are wit	hdrawn from consideration.		
5) Claim(s) is/are allowed.			
6) Claim(s) is/are rejected.			
7) Claim(s) is/are objected to.			
8) Claim(s) <u>1-37</u> are subject to restriction an	d/or election requirement.		
Application Papers			
9) The specification is objected to by the Exa		the Eveniner	
10) The drawing(s) filed on is/are: a) ☐  Applicant may not request that any objection			
11) The proposed drawing correction filed on _			
If approved, corrected drawings are required			
12) The oath or declaration is objected to by the			
Priority under 35 U.S.C. §§ 119 and 120			
13) Acknowledgment is made of a claim for fo	oreign priority under 35 U.S.C.	§ 119(a)-(d) or (f).	
a) ☐ All b) ☐ Some * c) ☐ None of:			
1. Certified copies of the priority docu	ments have been received.		
2. Certified copies of the priority docu	ments have been received in A	Application No	
<ul><li>3. Copies of the certified copies of the application from the Internation</li><li>* See the attached detailed Office action for</li></ul>	al Bureau (PCT Rule 17.2(a)).		
14) Acknowledgment is made of a claim for do	mestic priority under 35 U.S.C.	§ 119(e) (to a provisional application)	
<ul><li>a)  The translation of the foreign language</li><li>15) Acknowledgment is made of a claim for do</li></ul>			
Attachment(s)			
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-94 3) Information Disclosure Statement(s) (PTO-1449) Paper N	18) 5) Notice of	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152)	

Application/Control Number: 10/017,822

Art Unit: 1637

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-21, drawn to a method of protein preparation, wherein said preparation is immunoreactive with a monoclonal antibody produced by a hybridoma cell line and a method of using the protein preparation to isolate autoantibodies that are present in Alzheimer's disease, classified in class 530, subclass 412.
- II. Claims 22-27, drawn to a method of enhancing the ability of Alzheimer's disease antigen, classified in class 530, subclass 402.
- III. Claim 28-31, drawn to a monoclonal antibody and its method of production, classified in class 530, subclass 387.1.
- IV. Claims 32-37, drawn to a method of detecting autoantibodies that are present in Alzheimer's disease via use of protein preparation or a bovine microtubules, classified in class 436, subclass 500.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-IV are unrelated to each other. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions employ different sub-steps to achieve different outcomes. For example, the method of Group I is drawn to a protein preparation and its method of use in order to isolate autoantibodies, while the method of Group II is drawn to a method of enhancing the ability of an

Application/Control Number: 10/017,822

Art Unit: 1637

antigen to detect autoantibodies, the intent of the methods which require different sub-steps to achieve the desired outcome, rendering the searches non-coextensive in their scope. The method of Group III is drawn to a monoclonal antibody against an antigen against A68 which is different from that of the hybridoma cell line of Groups I and II, while the method of Group IV requires the use of bovine microtubules, an element not required by the methods of Groups I, II, and III.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

A telephone call was not made to request an oral election to the above restriction requirement due to the complex nature of the requirement (MPEP § 812.01).

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

## Inquiries

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Young J. Kim whose telephone number is (703) 308-9348. The Examiner can normally be reached from 8:30 a.m. to 7:00 p.m. Monday through Thursday. If attempts to reach the Examiner by telephone are unsuccessful, the Primary Examiner in charge of the prosecution, Dr. Kenneth Horlick, can be reached at (703)-308-3905. If the attempts to reach the above Examiners are unsuccessful, the Examiner's supervisor, Gary Benzion, can be reached at (703) 308-1119. Papers related to this application may be submitted to Art Unit 1637 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 CFR 1.6(d)). NOTE: If applicant does submit a paper by FAX, the original copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED, so as to avoid the processing of duplicate papers in the Office. The Fax number is (703) 746-

Application/Control Number: 10/017,822

Art Unit: 1637

3172. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Young J. Kim

8/11/03

KENNETH R. HORLICK, PH.D. PRIMARY EXAMINED

£ 3/3